



03 · ROADMAP & USE OF PROCEEDS

The sequence to a credible Series A.

INCORPORATE · FUND RUNWAY · SIGN THE COHORT · ACCELERATE · SCALE

A disciplined path from today's foundation to an institutional round — each step unlocking the next, and the whole sequence leading to **Sanabil** by the right door.

01 THE PATH

STEP	WHAT HAPPENS · WHY IT MATTERS
1 · Incorporate	Form the operating SAS and contribute the activity & IP. An entreprise individuelle cannot issue equity — this is the prerequisite to any raise.
2 · Fund runway	Secure non-dilutive capital (Bpifrance Bourse French Tech / i-Lab, regional grants, EIC) to extend runway without dilution.
3 · Pre-seed	Raise a pre-seed round to finish the product and convert the first founding-cohort clinics. Use of proceeds below.
4 · Sign the cohort	Turn the two clinics in discussion into signed founding-cohort clinics with deposits collected (€41,630). Signed, paying logos change the story.
5 · Accelerate	Enter the Sanabil x 500 Global accelerator — the early-stage, MENA-to-world door.
6 · Series A	With revenue and signed clinics, raise the institutional round with Sanabil's direct arm, anchored by a Kingdom go-to-market.

02 USE OF PROCEEDS — PRE-SEED

ALLOCATION	SHARE	PURPOSE
Product & technology	35%	Finish CLINIOS One Premium; security, data residency, multilingual depth.
Go-to-market & cohort	30%	Convert the founding cohort; introducer network; demos.
Team	25%	First key hires — clinical product, engineering, GTM.
Legal, SAS & runway	10%	Incorporation, IP, compliance, operating buffer.

03 WHAT UNLOCKS THE SERIES A

- ◆ Signed, paying clinics — a first handful of the founding cohort, with deposits collected.
- ◆ Recurring revenue at the €112k ARR price point, demonstrating the model.
- ◆ A Kingdom anchor — a Saudi/Gulf pilot clinic or partnership, the strongest signal for a PIF-backed investor.
- ◆ A built-out core team beyond the founder, de-risking execution.

The discipline is the strategy. *Each milestone earns the next round's valuation. The fastest way to a strong Series A is to arrive with signatures, not projections.*

CONFIDENTIAL · LONGEV'AI CLINICAL INTELLIGENCE · PARIS · 2026 · **NOT FOR DISTRIBUTION**